{"url":"https://lda.senate.gov/api/v1/filings/8c2e4478-b0b2-4c63-8a97-7bcdf7bbdcbf/","filing_uuid":"8c2e4478-b0b2-4c63-8a97-7bcdf7bbdcbf","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2019,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/8c2e4478-b0b2-4c63-8a97-7bcdf7bbdcbf/print/","filing_document_content_type":"text/html","income":null,"expenses":"270000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Leigh Owano","dt_posted":"2019-07-22T09:54:07.713000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"121 Seaport Blvd","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Boston","registrant_state":"MA","registrant_zip":"02210","registrant":{"id":400504482,"url":"https://lda.senate.gov/api/v1/registrants/400504482/","house_registrant_id":null,"name":"ALEXION PHARMACEUTICALS, INC.","description":"Global biopharmaceutical company","address_1":"121 Seaport Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Boston","state":"MA","state_display":"Massachusetts","zip":"02210","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATIE JONES","contact_telephone":"+1 857-338-8786","dt_updated":"2022-04-06T16:08:35.175195-04:00"},"client":{"id":191954,"url":"https://lda.senate.gov/api/v1/clients/191954/","client_id":12,"name":"ALEXION PHARMACEUTICALS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-10-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Orphan Drug Act, Drug pricing, ERISA","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64224,"prefix":null,"prefix_display":null,"first_name":"LEIGH","nickname":null,"middle_name":null,"last_name":"OWANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare Part B, Inpatient Hospital Reimbursement, Medicare Part D, Medicaid","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64224,"prefix":null,"prefix_display":null,"first_name":"LEIGH","nickname":null,"middle_name":null,"last_name":"OWANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}